Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences